Labiotech.eu

News and Trends 29 May 2020

Argenx Follows up Phase III Success with Giant €785M Global Offering

The Dutch biotech argenx has cashed in on recent positive phase III results by launching an enormous €784.7M ($862.5M) global share offering. Argenx’s fundraise swiftly follows the announcement of phase III trial results earlier this week, where its lead candidate antibody drug, efgartigimod, improved motor symptoms of patients with the chronic autoimmune disease myasthenia gravis. […]

May 29, 2020 - 2 minutesmins - By Jonathan Smith

central nervous system epilepsy parkinsons disease

News and Trends 29 May 2020

Spanish Neurology Biotech Launches with €7.6M Series A

Accure Therapeutics, a neurology biotech targeting central nervous system (CNS) conditions such as multiple sclerosis and Parkinson’s disease, has launched in Barcelona with a Series A of €7.6M. Alta Life Sciences, a life science venture capital firm based in the same city, and the Spanish governmental institution The Centre for Technological and Industrial Development funded […]

May 29, 2020 - 3 minutesmins - By Helen Albert

News and Trends 28 May 2020

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy

Lyon-based biopharmaceutical company Tollys has closed a Series A funding round of €2.3M to bring its lead RNA immunotherapy candidate to clinical trials in people with bladder cancer. The round was closed on the basis of the company reaching preclinical proof-of-concept for the drug. It brings the total amount raised by Tollys to €6.4M since […]

May 28, 2020 - 2 minutesmins - By Laura Cowen

News and Trends 28 May 2020

MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience

The US-based big pharma MSD has entered the race to be the first to develop an effective vaccine for Covid-19 by acquiring Austrian biotech Themis Bioscience and its vaccine technology for an undisclosed amount. MSD has been a bit slower than some of its contemporaries to announce its plans regarding a potential treatment or vaccine […]

May 28, 2020 - 3 minutesmins - By Helen Albert

gates foundation oxitec malaria mosquito

News and Trends 27 May 2020

‘Just Add Water’ GM Mosquitoes Suppress Wild Population by 95%

Water-soluble capsules containing the eggs of genetically modified mosquitoes developed by the UK company Oxitec have reduced the mosquito population in a dengue-infected urban environment in Brazil by 95% after 13 weeks. Aedes aegypti mosquitoes carry a number of infections including dengue, Zika, chikungunya, and yellow fever. Dengue has increased almost 15-fold over the last […]

May 27, 2020 - 4 minutesmins - By Helen Albert

Expert Advice 27 May 2020

Why Listening to Patient Organizations is Key in Drug Development

As the biotech industry flourishes and therapies become more targeted and personalized, the need for drug developers to interact with patients is increasing as well. While patient organizations took a backseat in the past, they are continuously gaining importance in drug development today. Nowadays, talking with patient organizations has become paramount for successful drug development, […]

May 27, 2020 - 11 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 26 May 2020

Argenx’s Rare Disease Treatment Strikes Gold in Phase III

The Dutch biotech argenx aims to apply for FDA approval of its lead candidate efgartigimod after the first-in-class drug improved motor symptoms of the autoimmune disease myasthenia gravis in a phase III trial. The phase III trial tested the effect of efgartigimod in 167 patients with generalized myasthenia gravis. In this incurable chronic condition, the […]

May 26, 2020 - 3 minutesmins - By Jonathan Smith

In Depth 25 May 2020

Could Cell Therapy Target the Symptoms of Severe Covid-19?

The excessive inflammatory response seen in the most serious cases of Covid-19, along with shortages of ventilators, has caused a healthcare crisis in many countries around the world. Could cell therapy provide an answer to this dilemma? Most people who become infected with Covid-19 experience symptoms such as a dry cough and mild fever, and […]

May 25, 2020 - 5 minutesmins - By Helen Albert

News and Trends 25 May 2020

Evonik and Beiersdorf Team Up to Turn CO₂ into Skin Care Products

The German companies Evonik and Beiersdorf will work together on a joint research project to investigate how bacteria can be used to turn carbon dioxide (CO₂) and water into raw materials for skincare products. The process will be built on Evonik’s artificial photosynthesis technology – being developed independently of this project in collaboration with Siemens […]

May 25, 2020 - 2 minutesmins - By Laura Cowen

balmes transplantation kidney disorders 1

News and Trends 22 May 2020

Phase II Fail Ends Swiss-US Drug for Rare Kidney Disease

An initially promising drug has failed to show benefits in a phase II trial for the rare kidney disease focal segmental glomerulosclerosis (FSGS), prompting the US biotech ChemoCentryx and its Swiss collaborator Vifor Pharma to drop it for this indication. Topline results from the phase II trial showed that 12 weeks of treatment with the […]

May 22, 2020 - 2 minutesmins - By Anita Chakraverty

Interview 21 May 2020

What 2019 Can Teach About European Biotech Investments Going Forward

Following 2018’s bumper harvest for equity funding in European biotech, 2019 proved even more lucrative, particularly for private biotech companies. What are the biggest investment lessons learned from 2019, and how could Covid-19 change the dynamic in 2020? With the coronavirus pandemic thrusting global industry sectors into chaos, investors and entrepreneurs need to understand the […]

May 21, 2020 - 9 minutesmins - By Jonathan Smith

News and Trends 20 May 2020

Phase II Success for Once-a-Day Eye Drops after Cataract Surgery

A nanoparticle steroid therapy developed by Swiss biotech Oculis has reduced eye pain and inflammation in a phase II trial in cataract surgery patients. This is the second positive phase II this year for the company, which closed a €31M Series B fundraising round at the beginning of 2019. In February this year, Oculis also […]

May 20, 2020 - 3 minutesmins - By Helen Albert

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Argenx Follows up Phase III Success with Giant €785M Global Offering

Spanish Neurology Biotech Launches with €7.6M Series A

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy

MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience

‘Just Add Water’ GM Mosquitoes Suppress Wild Population by 95%

Why Listening to Patient Organizations is Key in Drug Development

Argenx’s Rare Disease Treatment Strikes Gold in Phase III

Could Cell Therapy Target the Symptoms of Severe Covid-19?

Evonik and Beiersdorf Team Up to Turn CO₂ into Skin Care Products

Phase II Fail Ends Swiss-US Drug for Rare Kidney Disease

What 2019 Can Teach About European Biotech Investments Going Forward

Phase II Success for Once-a-Day Eye Drops after Cataract Surgery

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!